Zenith Drugs

Which are the latest news on Zenith Drugs?

Why is Zenith Drugs Ltd falling/rising?

As of 05-Sep, Zenith Drugs Ltd's stock price is rising to 42.75, reflecting a 7.28% increase due to strong sector performance and heightened investor interest, despite longer-term declines. The stock's current performance suggests a potential recovery phase.

As of 05-Sep, Zenith Drugs Ltd's stock price is rising, currently at 42.75, reflecting a change of 2.9 or 7.28% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 7.73% today, indicating strong relative performance. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 219.44% compared to the 5-day average, suggesting heightened interest and confidence among investors. <BR><BR>While the stock has shown negative performance over longer periods, such as a decline of 14.84% year-to-date and 39.75% over the past year, the current day's performance indicates a positive shift. Furthermore, the stock's price is higher than its 5-day moving averages, although it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, which may suggest a potential recovery phase. Overall, the combination of strong sector performance and increased trading activity appears to be driving the stock's rise on this particular day.

What does Zenith Drugs do?

Zenith Drugs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently converted to a Public Limited Company. It has a market cap of INR 76 Cr, with key metrics including a P/E ratio of 18.00 and a debt-equity ratio of 0.72.

Overview:<BR>Zenith Drugs Ltd is a company operating in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap.<BR><BR>History:<BR>Zenith Drugs Limited was originally incorporated on November 15, 2000, as a Private Limited Company under the name "Zenith Drugs Private Limited." The company was later converted into a Public Limited Company, and its name was changed to "Zenith Drugs Limited" following the issuance of a Fresh Certificate of Incorporation on September 13, 2023. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 76 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.72<BR>Return on Equity: 5.49%<BR>Price-to-Book: 1.06<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Zenith Drugs?

Zenith Drugs' peers include Vineet Laborator, Onyx Biotec, Vilin Bio Med, Ajooni Biotech, Bharat Immunolog, Samrat Pharma, Source Natural, Sunil Healthcare, Amwill Health, and Phaarmasia. Zenith Drugs has below-average management risk, growth, and capital structure, with the lowest 1-year return among peers at -38.58%.

Peers: The peers of Zenith Drugs are Vineet Laborator, Onyx Biotec, Vilin Bio Med, Ajooni Biotech, Bharat Immunolog, Samrat Pharma, Source Natural, Sunil Healthcare, Amwill Health, and Phaarmasia.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health, while Good management risk is found at Source Natural. Average management risk is present at Onyx Biotec and Samrat Pharma, while Below Average management risk is noted at Vineet Laborator, Zenith Drugs, Vilin Bio Med, Ajooni Biotech, Bharat Immunolog, Sunil Healthcare, and Phaarmasia. In terms of Growth, Good growth is seen at Ajooni Biotech and Sunil Healthcare, Average growth is found at Vilin Bio Med and Onyx Biotec, while Below Average growth is noted at Vineet Laborator, Zenith Drugs, Bharat Immunolog, Samrat Pharma, Source Natural, and Phaarmasia. For Capital Structure, Excellent capital structure is observed at Samrat Pharma and Amwill Health, Good capital structure is found at Source Natural, while Below Average capital structure is noted at Vineet Laborator, Zenith Drugs, Vilin Bio Med, Bharat Immunolog, Sunil Healthcare, and Phaarmasia.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vilin Bio Med at 74.35%, while the lowest is Zenith Drugs at -38.58%, indicating a significant decline compared to its peers. Additionally, Ajooni Biotech, Bharat Immunolog, and Zenith Drugs have negative six-month returns.

How big is Zenith Drugs?

Summary could not be generated.

As of 14th August, Zenith Drugs Ltd has a market capitalization of 73.74 Cr, which categorizes it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the reporting period of March 2024, the Shareholder's Funds amount to 62.26 Cr, and the Total Assets are valued at 134.97 Cr.

Is Zenith Drugs overvalued or undervalued?

As of November 18, 2025, Zenith Drugs is considered overvalued at a price of 57.35, with a PE ratio of 13.74 and a significant underperformance of -39.05% compared to the Sensex, especially when compared to its peers like Sun Pharma and Divi's Lab, which have much higher PE ratios.

As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued.

How has been the historical performance of Zenith Drugs?

Zenith Drugs has shown significant growth over the past three years, with net sales increasing from 91.66 Cr in March 2022 to 131.62 Cr in March 2024, and operating profit rising from 7.85 Cr to 19.03 Cr. Despite negative cash flow from operations, the company has expanded its asset base and achieved strong profitability improvements.

Answer:<BR>The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, from 68.58 Cr in March 2022 to 134.97 Cr in March 2024, reflecting a robust expansion strategy. Cash flow from operating activities has been negative in recent years, but cash flow from investing activities turned positive in March 2024, contributing to a net cash inflow of 8.00 Cr. Overall, Zenith Drugs has demonstrated strong growth in sales and profitability, alongside an expanding asset base, despite challenges in cash flow from operations.

Who are the top shareholders of the Zenith Drugs?

The top shareholders of Zenith Drugs include promoter Ajay Singh Dassundi with 22.52%, individual investors with 25.56%, and public shareholder Praveen Mudunuri at 1.21%. There are also two foreign institutional investors holding 0.06%, and no mutual funds are currently invested in the company.

The top shareholders of Zenith Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ajay Singh Dassundi, owning 22.52% of the company. Additionally, individual investors collectively hold 25.56% of the shares. In terms of institutional investors, there are two foreign institutional investors (FIIs) that hold a small portion, specifically 0.06%. The highest public shareholder is Praveen Mudunuri, with a holding of 1.21%. There are no mutual funds currently holding shares in the company.

What is the technical trend for Zenith?

As of May 30, 2025, Zenith's technical trend has shifted to mildly bearish, supported by bearish signals from the MACD, moving averages, and Dow Theory, despite a conflicting bullish KST signal.

As of 30 May 2025, the technical trend for Zenith has changed from sideways to mildly bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Dow Theory confirms a mildly bearish outlook on both weekly and monthly time frames. Although the KST shows a bullish signal on the weekly, the overall sentiment is dampened by the bearish signals from the Bollinger Bands and the OBV, which is mildly bearish on the weekly but bullish on the monthly. The stock has underperformed significantly against the Sensex over the past month and year-to-date, further reinforcing the bearish sentiment.

When is the next results date for Zenith?

No Upcoming Board Meetings

Has Zenith declared dividend?

Zenith Drugs Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 17, 2024. While the dividend yield is 0.73%, total returns have varied significantly, showing a -22.92% return over the last 6 months and a modest 9.75% return over the past year.

Zenith Drugs Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.73%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.92%, the dividend return was 0%, resulting in a total return of -22.92%.<BR><BR>Over the past year, the price return was 8.98%, the dividend return was 0.77%, leading to a total return of 9.75%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>For the 5-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Zenith has declared a dividend, the total returns over various periods show mixed results, with significant negative returns in the short term and modest positive returns in the longer term. The dividend yield is relatively low, indicating that while dividends are being paid, the overall performance may not be strong.